-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) announced that SIM0712, an oral small molecule degrader with target signal transduction and transcription initiation factor 6 (“STAT6”) independently developed by the Group, has received a drug clinical trial approval notice issued by the China National Drug Administration to conduct clinical trials for the treatment of atopic dermatitis.

Zhitongcaijing·11/16/2026 10:17:18
Listen to the news
Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) announced that SIM0712, an oral small molecule degrader with target signal transduction and transcription initiation factor 6 (“STAT6”) independently developed by the Group, has received a drug clinical trial approval notice issued by the China National Drug Administration to conduct clinical trials for the treatment of atopic dermatitis.